Join us for an Agilent Cell Analysis Virtual Event

A Next Generation Tool Bench for Virology Research

Thursday,
November 12, 2020

09:00 - 11:00am PDT
11:00 - 01:00pm CDT
12:00 - 02:00pm EDT

The next generation of vaccines and anti-viral therapies require a new generation of analysis tools.

Research advancing our understanding of host-pathogen and host-immune response to virus infection is critical and timely under the current global pandemic.

Discover Agilent’s new end-to-end solutions for virology disease research, drug discovery and vaccine development, enabling translational researchers and developers to address present and future challenges in global human health and infectious disease.

Register for our Virtual Roadshow, where we will be joined by Dr. Peter Mullen from the University of California, Los Angeles. Learn also from Agilent product experts who will showcase relevant product lines and assays, including Seahorse XF technology, xCELLigence RTCA, NovoCyte Flow Cytometry & BioTek Instruments, supported by published application examples from the field.

Meet our presenters

Viral hijacking of cellular metabolism

Dr. Peter Mullen is an Assistant Project Scientist in the laboratory of Dr. Heather Christofk in the Department of Biological Chemistry at the David Geffen School of Medicine at UCLA. Dr. Mullen earned a M.Biochem. from the University of Oxford, England, and a Ph.D. from the University of Basel, Switzerland. His research focuses on how viruses alter the metabolism of host cells, and how these changes can be exploited to develop therapeutic strategies against multiple viruses.

Dr. Peter Mullen
Assistant Project Scientist
University of California, Los Angeles

Seahorse XF Reveals Bioenergetic Impact in Virology

Dr. Bittman joined Seahorse Bioscience in 2008. He earned his Ph.D. degree in Neuroscience from the University of Connecticut in 1998, where he researched mechanisms involved in neuronal cell fate determination. Dr. Bittman continued his research at University College London from 1998 to 2001 and the University of Pennsylvania from 2001 to 2004. From 2004 to 2008, Dr. Bittman was the sales and service representative for Phase 3 Imaging Systems, Inc., a microscopy applications company located in Philadelphia. At Seahorse, Dr. Bittman is the East Coast Field Applications Scientist. He handles, trainings, service and support.

Dr. Kevin Bittman
Field Applications Scientist
Cell Analysis Division, Agilent

Rapid functional evaluation of virus-neutralizing antibodies and anti-viral drugs using multi-parametric live cell analysis

Dr. Yama A. Abassi is Head of Strategic Business Development within Cell Analysis Division at Agilent. He received his undergraduate degree in biochemistry with honors from the State University of New York/Stony Brook in 1992, and a PhD in Molecular, Cell, and Developmental Biology from the University of California at Santa Barbara in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research as an NIH post-doctoral fellow in 1999 and spent the next few years studying oncogene signaling pathways and their role in cancer biology.

Dr. Abassi joined ACEA Biosciences in 2003 to help develop a new technology for studying cells using microelectronics. Dr. Abassi’s efforts in this field have earned him numerous publications and patents and have led to the successful development and commercialization of the xCELLigence Real-Time Cell Analysis (RTCA) instrument globally. Dr. Abassi continues to pursue his research interests in developing technologies, applications and solutions using real-time cell analysis approach for different disciplines within the health science field such as immunotherapy, virology and pre-clinical safety/tox.

Dr. Yama Abassi
Head of Strategic Business Development, Cell Analysis Division, Agilent

Focus on Virology: Applications to Enable Discovery

Kristen N. Peters Olson, Ph.D. is an Imaging Specialist and Field Applications Scientist for BioTek Instruments in the Greater Boston Area. She received her Ph.D. in Molecular Microbiology and Immunology and Pathobiology from the University of Missouri in 2012. Her dissertation focused on the Yersinia pestis effector protein, YopK, in modulating cell death modality during pneumonic plague. This in vivo infection model focused on the lung immune response to pneumonic plague and was performed in BSL3 conditions at the University of Missouri Laboratory for Infectious Disease Research. In her postdoctoral position at University of Massachusetts Medical School, she studied efferocytosis and its impact on the innate and adaptive immune response in the lung during tuberculosis. To broaden her infectious disease expertise, she accepted a postdoctoral position at the National Emerging Infectious Diseases Laboratories at Boston University, focused on Ebola, Marburg, and Lassa viruses. There, she collaborated with academic colleagues and industry leaders to develop a no-wash diagnostic assay based on SERS technology for the detection of hemorrhagic fever viruses in the field. With the onset of the Zika epidemic, she shifted her focus to Zika virus and developed a novel human placental explant model of infection to understand the cellular tropism, host response, and how the virus causes such severe impact to the developing fetus. This diverse background focusing on host-pathogen interaction in multiple disease models using a variety of assays prepared her for her current position. As an Imaging Specialist for BioTek Instruments, she assists researchers in learning automated imaging technology, developing protocols to best suit their needs, and providing suggestions to improve their research.

Dr. Kristen Olson
Imaging Specialist and Field Applications Scientist
BioTek Instruments, a part of Agilent

For Research Use Only. Not for use in diagnostic procedures.

©2020 Agilent Technologies